Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exicure Inc.

www.exicuretx.com

Latest From Exicure Inc.

Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea

Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.

Business Strategies Commercial

Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal

In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.

Deals Business Strategies

Finance Watch: Rakuten Aspyrian Raises $150m VC Round For Laser-Activated Cancer Drugs

Private investors, including Japanese e-commerce mogul Hiroshi Mikitani, backed a $150m Series C round for Rakuten Aspyrian and its photoimmunotherapy platform. Also, pharma-backed therapeutic video game developer Akili boosts Series C to $68m, and Summit garners additional BARDA funding.

Financing Business Strategies

Appointments: Novartis And GSK Fill Key R&D Roles, Celgene Board Changes And Others

This week's announcements include Novartis's replacement for Vas Narasimhan as head of global development, GlaxoSmithKline's new head of worldwide business development for pharmaceuticals research & development, new board members at Celgene, an interim CEO at Nordic Nanovector, and changes at Vectura, PureTech Health and Exicure.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Dermatology
  • Immune Disorders
  • Infectious & Viral Diseases
  • Respiratory, Pulmonary
  • Alias(es)
  • AuraSense Therapeutics LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Exicure Inc.
  • Senior Management
  • David A Giljohan, PhD, CEO
    David S Snyder, CFO
    Jocelyn Trokenheim , VP, Head, Bus. Dev.
    Matthias Schroff , PhD, COO
  • Contact Info
  • Exicure Inc.
    Phone: (847) 673-1700
    8045 Lamon Ave.
    Ste. 410
    Skokie, IL 60077
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register